InvestmentJun 30, 2026, 04:47 PM
Abivax Launches $600M Public Offering of ADSs
AI Summary
Abivax S.A. announced the launch of an underwritten public offering of approximately $600 million in American Depositary Shares (ADSs) in the United States. The company intends to use the net proceeds primarily for the potential commercialization of its lead drug candidate, obefazimod, in the US, and for clinical research and development related to ulcerative colitis and Crohn's disease. The offering is subject to market conditions, and the final terms will be determined after a book-building process, with trading of ordinary shares on Euronext expected to be suspended temporarily.
Key Highlights
- Abivax launched an underwritten public offering of approximately $600 million in American Depositary Shares (ADSs).
- The offering includes an option for underwriters to purchase up to an additional 15% of ADSs.
- Proceeds will fund potential commercialization of obefazimod in the US and clinical R&D for ulcerative colitis and Crohn's disease.
- Company, board members, and executive officers are subject to a 60-day contractual lock-up.
- Leerink Partners, Morgan Stanley, Piper Sandler, and Guggenheim Securities are joint bookrunning managers.
Price Impact
More from ABVX